Get the Stockscreener App
1.31
4.38%
-0.06
Macrogenics Inc stock is traded at $1.31, with a volume of 731.58K.
It is down -4.38% in the last 24 hours and down -16.56% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.37
Open:
$1.39
24h Volume:
731.58K
Relative Volume:
0.65
Market Cap:
$112.30M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-0.8291
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
-13.82%
1M Performance:
-16.56%
6M Performance:
-58.81%
1Y Performance:
-68.20%
1-Day Range:
$1.304
$1.40
1-Week Range:
$1.304
$1.57
52-Week Range:
$0.9897
$5.77
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.31 | 112.30M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
A Closer Look at Macrogenics Inc (MGNX) Stock Gains - investchronicle.com
MacroGenics (NASDAQ:MGNX) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead By Investing.com - Investing.com India
MacroGenics’ SWOT analysis: biotech firm’s stock faces pivotal year ahead - Investing.com
MacroGenics secures $70M from Sagard in royalty deal By Investing.com - Investing.com Nigeria
MacroGenics: Working On That Road To Recovery (NASDAQ:MGNX) - Seeking Alpha
MacroGenics lands $70M 'infusion of cash' to advance clinical programs - The Business Journals
MGNX LAWSUIT ALERT: Levi & Korsinsky Notifies MacroGenics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Traders Buy High Volume of MacroGenics Call Options (NASDAQ:MGNX) - Defense World
MacroGenics (MGNX) Secures $70M Upfront Payment in Royalty Deal - GuruFocus
MacroGenics signs financial deal with Sagard for retifanlimab - Seeking Alpha
MacroGenics, Inc. and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement - MarketScreener
MacroGenics, Sagard Sign Zynyz Royalty Purchase Deal - MarketScreener
MacroGenics at Goldman Sachs Conference: Strategic Pipeline Expansion - Investing.com Australia
United Natural Foods, Insmed, MacroGenics - TradingView
Transcript : MacroGenics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - marketscreener.com
MacroGenics at Goldman Sachs Conference: Strategic Pipeline Expansion By Investing.com - Investing.com Canada
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Roy - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Shares Bought by Bank of America Corp DE - Defense World
MacroGenics secures $70M from Sagard in royalty deal - Investing.com Australia
MacroGenics, Sagard Healthcare enter into ZYNYZ royalty purchase - TipRanks
MacroGenics stock soars on royalty deal with Sagard By Investing.com - Investing.com Nigeria
MacroGenics stock soars on royalty deal with Sagard - Investing.com Australia
MacroGenics Enters Royalty Purchase Agreement with Sagard - TipRanks
MacroGenics (MGNX) Secures $70 Million Through Royalty Agreement | MGNX Stock News - GuruFocus
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement - GlobeNewswire
Would I Choose Macrogenics Inc (NASDAQ: MGNX) Stock At Any Point In Time? - Stocksregister
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug TrialHagens Berman - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Ameriprise Financial Inc. Sells 26,544 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Brokerages Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $5.71 - Defense World
HAGENS BERMAN, SHAREHOLDER ADVOCATES, Encourages MacroGenics (MGNX) Investors With Significant Losses to Contact Its Attorneys, 6-Day Application Deadline is Approaching - ACCESS Newswire
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MacroGenics (MGNX) Investors With Significant Losses to Contact Its Attorneys, 5-Day Application Deadline is Approaching in Securities Class Action - ACCESS Newswire
MacroGenics to Present at the Goldman Sachs 46th Annual Global H - GuruFocus
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | MGNX Stock News - GuruFocus
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewswire
MacroGenics Executives Set for Major Goldman Sachs Healthcare Conference Presentation: Watch Live - Stock Titan
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024 – MGNX - ACCESS Newswire
MacroGenics (NASDAQ:MGNX) Upgraded to Hold at Wall Street Zen - Defense World
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges By Investing.com - Investing.com South Africa
MacroGenics’ SWOT analysis: biotech firm’s stock faces pipeline challenges - Investing.com
Lazard Asset Management LLC Purchases New Position in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Northern Trust Corp Has $1.76 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Q2 Earnings Forecast for MacroGenics Issued By B. Riley - Defense World
MacroGenics Holds Annual Stockholders Meeting on May 21 - TipRanks
B. Riley Issues Pessimistic Forecast for MacroGenics (NASDAQ:MGNX) Stock Price - Defense World
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher - simplywall.st
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Macrogenics Inc Stock (MGNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):